# Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma

> **NCT03927105** · PHASE2 · COMPLETED · sponsor: **University of Michigan Rogel Cancer Center** · enrollment: 4 (actual)

## Conditions studied

- Peripheral T Cell Lymphoma

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** cabiralizumab

## Key facts

- **NCT ID:** NCT03927105
- **Lead sponsor:** University of Michigan Rogel Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-25
- **Primary completion:** 2019-11-01
- **Final completion:** 2023-07-06
- **Target enrollment:** 4 (ACTUAL)
- **Last updated:** 2026-05-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03927105

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03927105, "Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT03927105. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*